Romain Loyon

ORCID: 0000-0001-8039-7893
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • Cancer, Lipids, and Metabolism
  • Peroxisome Proliferator-Activated Receptors
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Inflammatory mediators and NSAID effects
  • Nuclear Receptors and Signaling
  • T-cell and B-cell Immunology
  • IL-33, ST2, and ILC Pathways
  • Pluripotent Stem Cells Research
  • Biomedical Ethics and Regulation
  • Macrophage Migration Inhibitory Factor
  • Eosinophilic Esophagitis
  • Metabolism, Diabetes, and Cancer
  • Virus-based gene therapy research
  • Immune cells in cancer
  • Renal and related cancers
  • Microfluidic and Capillary Electrophoresis Applications
  • 3D Printing in Biomedical Research
  • Pancreatic and Hepatic Oncology Research
  • Epigenetics and DNA Methylation
  • Cancer Genomics and Diagnostics
  • Microfluidic and Bio-sensing Technologies
  • Amoebic Infections and Treatments

Inserm
2016-2025

Établissement Français du Sang
2022-2025

Université de franche-comté
2016-2025

Université Bourgogne Franche-Comté
2016-2023

Centre Hospitalier Universitaire de Besançon
2020

Ludwig Cancer Research
2018-2019

University of Lausanne
2018-2019

Breast Cancer (BC) is the most common type of cancer in women around world and 70% cases are hormone-receptor positive (HR+). In 40% cases, a key mechanism endocrine resistance to standard first line mutation ligand-binding domain (LBD) Estrogen Receptor 1 (ESR1) encoding estrogen receptor α (ER). Most ESR1 mutations that occur at positions 537 538 have been associated with poor clinical outcomes. potential provide neoantigens. This study aims identify if generate specific T cell responses...

10.1186/s13058-025-01962-6 article EN cc-by-nc-nd Breast Cancer Research 2025-02-07

Group 2 innate lymphoid cells (ILC2s) play a critical role in protection against helminths and diverse inflammatory diseases by responding to soluble factors such as the alarmin IL-33, that is often overexpressed cancer. Nonetheless, regulatory dictate ILC2 functions remain poorly studied. Here, we show peroxisome proliferator-activated receptor gamma (PPARγ) selectively expressed ILC2s humans mice, acting central functional regulator. Pharmacologic inhibition or genetic deletion of PPARγ...

10.1038/s41467-021-22764-2 article EN cc-by Nature Communications 2021-05-05

Tissue-resident memory (TRM) T cells have emerged as key players in cancer immunosurveillance, and their presence has been linked to a favorable clinical outcome solid patients. Liver metastases exhibit highly immunosuppressive tumor microenvironment, however, the role impact of TRM cell infiltration colorectal remain elusive. The expression several tissue residency activation biomarkers investigated on tumor-infiltrating lymphocytes isolated from 26 patients' liver (CRC metastases) compared...

10.1080/2162402x.2025.2455176 article EN cc-by-nc OncoImmunology 2025-01-23

CD226 has been reported to participate in the rescue of CD8+ T cell dysfunction. In this study, we aimed assess prognostic value tumor-infiltrating lymphocytes (TILs) derived from colorectal cancer (CRC) liver metastases treated with chemotherapy and radical surgery. TILs 43 were isolated analyzed ex vivo using flow cytometry. CD155 CD3 levels tumor microenvironment assessed by immunohistochemistry. Exploration validation biological processes highlighted study performed bioinformatics...

10.1038/s41423-023-00978-2 article EN cc-by Cellular and Molecular Immunology 2023-01-30

Immune checkpoint blockade has proven its efficacy in hypermutated subtypes of metastatic colorectal cancers (mCRC). Immunogenic potential can also be observed with conventional chemotherapies, but this property never been explored thoroughly CRC patients. The therapeutic arsenal includes oxaliplatin, a well-characterized platinum drug already described as immunogenic. Here, we investigated the impact oxaliplatin-based treatment on mCRC immunopeptidome. We demonstrated that...

10.1002/ijc.32620 article EN International Journal of Cancer 2019-08-09

Several distinct innate lymphoid cell (ILC) populations have been recently identified and shown to play a critical role in the immediate immune defense. In context of tumors, there is evidence support dual for ILCs with pro- or antitumor effects, depending on ILC subset type cancer. This ambivalent has particularly well-described colorectal cancer models (CRC), but presence evolution peripheral blood metastatic CRC (mCRC) patients not yet explored. Here, we investigated distribution subsets...

10.3389/fimmu.2019.02121 article EN cc-by Frontiers in Immunology 2019-09-06

Combining immunogenic cell death-inducing chemotherapies and PD-1 blockade can generate remarkable tumor responses. It is now well established that TGF-β1 signaling a major component of treatment resistance contributes to the cancer-related immunosuppressive microenvironment. However, whether remains an obstacle immune checkpoint inhibitor efficacy when immunotherapy combined with chemotherapy still be determined. Several syngeneic murine models were used investigate role neutralization on...

10.1080/2162402x.2022.2144669 article EN cc-by-nc OncoImmunology 2022-11-12

Despite successful introduction of NK-based cellular therapy in the treatment myeloid leukemia, potential use NK alloreactivity solid malignancies is still elusive. We performed a phase I clinical trial to assess safety and efficacy situ delivery allogeneic cells combined with cetuximab liver metastasis gastrointestinal origin. The conditioning chemotherapy was administrated before injection via hepatic artery. Three escalating doses were tested (3.106, 8.106 12.106 cells/kg) following by...

10.1080/2162402x.2018.1424673 article EN OncoImmunology 2018-03-14

Natural killer (NK) cells are innate effector lymphocytes widely involved in cancer immunosurveillance. In this study, we described three circulating NK cell subsets patients with non-small lung (NSCLC). Compared to healthy donors (HD), lower rate of the cytotoxic CD56dim CD16+ was found NSCLC (76.1% vs 82.4%, P = 0.0041). contrast, CD56bright similar between and HD. We showed a higher subset CD16− phenotype (16.7% 9.9% 0.0001). The degranulation property cytokines production were mainly...

10.1080/2162402x.2018.1527498 article EN OncoImmunology 2018-10-19

Background The positive role of CD8+ tumor-infiltrating lymphocytes (TIL) in patients with colorectal cancer (CRC) has been well described but the prognostic value CD4 T cell subsets remained to be investigated. In this study, we expanded TIL from surgically resected liver metastases CRC and characterized phenotype expanded-CD4 cells. Methods Liver were 23 CRC. Tumors enzymatically digested cultured high dose interleukin-2 for up 5 weeks. reactivity cultured-T cells measured by flow...

10.1136/jitc-2020-001478 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2020-11-01

Abstract NK cells are critical for innate immunity–mediated protection. The main roles of rely on their cytotoxic functions or depend the tuning Th1 adaptive immunity by IFN-γ. However, precise influence inflammatory cytokines cell and CD4 T lymphocyte interactions was never investigated. In this study, we provide evidence that IL-21, a cytokine produced during chronic inflammation infectious diseases, promotes differentiation specific subset coexpressing CD86 HLA-DR lacking NKp44. More...

10.4049/jimmunol.1501147 article EN The Journal of Immunology 2016-05-28

Abstract In addition to improving insulin sensitivity in type 2 diabetes, the thiazolidinedione family of compounds and pharmacologic activation their best-characterized target PPARγ have been proposed as a therapeutic option for cancer treatment. this study, we reveal new mode action rosiglitazone that can contribute tumorigenesis. Rosiglitazone activated tumorigenic paracrine communication program subset human melanoma cells involves secretion cytokines, chemokines, angiogenic factors....

10.1158/0008-5472.can-18-0912 article EN Cancer Research 2018-09-05

Angiopoietin‐2 (ANGPT2) is a prognostic factor in metastatic colorectal cancer (CRC). Nevertheless, it remains to be elucidated which molecular characteristics make up the ANGPT2‐related poor‐prognosis CRC subset. Public transcriptomic datasets were collected from Gene Expression Omnibus GEO and with TCGAbiolinks R‐package for TCGA. After appropriate normalization, differential expression analysis was performed using Benjamini Hochberg method false discovery rate. Plasma two prospective...

10.1002/ijc.32993 article EN International Journal of Cancer 2020-03-29

Abstract Telomerase is a prototype-shared tumor Ag and represents an attractive target for anticancer immunotherapy. We have previously described promiscuous immunogenic HLA-DR–restricted peptides derived from human telomerase reverse transcriptase (hTERT) referred as universal cancer peptide (UCP). In nonsmall cell lung cancer, the presence of spontaneous UCP-specific CD4 T responses increases survival chemotherapy-responding patients. However, precise mechanisms hTERT’s uptake, processing,...

10.4049/jimmunol.1502633 article EN The Journal of Immunology 2016-08-02

Pancreatic ductal adenocarcinoma (PDAC) is marked by molecular heterogeneity and poor prognosis. Among the stemness-related transcription factors, Spalt-like Transcription Factor 4 (SALL4) correlated with unfavorable outcomes; however, its roles in PDAC remain unclear. SALL4high expression defines a subpopulation characterized shortened patient survival. Although SALL4 was mostly evaluated tumor cells, our findings identify this embryonic factor as new biomarker PDAC-derived stroma. Gene...

10.1002/1878-0261.13370 article EN cc-by Molecular Oncology 2023-01-01

The understanding of cell-cell and cell-matrix interactions via receptor ligand binding relies on our ability to study the very first events their contact. Of particular interest is interaction between a T cell its cognate peptide-major histocompatibility complex. Indeed, analyzing kinetics cellular avidity in large-scale low-cost fast sorting would largely facilitate access cell-based cancer immunotherapies. We thus propose microfluidic tool able independently control two types micro-sized...

10.1039/d3lc00400g article EN cc-by-nc Lab on a Chip 2023-01-01
Coming Soon ...